본문 바로가기
KERD
논문KCI 등재

Evaluation and Management of Extrahepatic Manifestations of Nonalcoholic Fatty Liver Disease

Donghee Kim|Aijaz Ahmed|Wijarnpreecha Karn|Elizabeth S. Aby
대한간학회 (The korean Association for the Study of the Liver)|2021.04|Clinical and Molecular Hepatology|제27권 제2호|pp. 221-235|DOI 10.3350/cmh.2020.0239

2

조회

0

다운로드

5

인용

0

참고문헌

키워드

Cardiovascular diseasesFatty liverTherapeuticsLiver cirrhosisNon-alcoholic fatty liver disease

초록

Nonalcoholic fatty liver disease (NAFLD) is a multisystemic disease and a rapidly growing cause of chronic liver disease in children and adults worldwide. Diagnosis and management of extrahepatic manifestations of NAFLD, including cardiovascular disease (CVD), type 2 diabetes mellitus, metabolic syndrome, chronic kidney disease, obstructive sleep apnea, polycystic ovarian syndrome, hypothyroidism, psoriasis, and extrahepatic malignancy are crucial for the treatment of patients with NAFLD. The leading cause of death in NAFLD is primarily from CVD, followed by liver-related mortality, extrahepatic cancer, liver cancer, and diabetes-related mortality. Therefore, clinicians need to identify high-risk patients earlier in the disease course and be aware of the extrahepatic manifestations of NAFLD to improve liver disease outcomes. In this review, we focus on the monitoring and management of the extrahepatic manifestations of NAFLD.

Abstract

Nonalcoholic fatty liver disease (NAFLD) is a multisystemic disease and a rapidly growing cause of chronic liver disease in children and adults worldwide. Diagnosis and management of extrahepatic manifestations of NAFLD, including cardiovascular disease (CVD), type 2 diabetes mellitus, metabolic syndrome, chronic kidney disease, obstructive sleep apnea, polycystic ovarian syndrome, hypothyroidism, psoriasis, and extrahepatic malignancy are crucial for the treatment of patients with NAFLD. The leading cause of death in NAFLD is primarily from CVD, followed by liver-related mortality, extrahepatic cancer, liver cancer, and diabetes-related mortality. Therefore, clinicians need to identify high-risk patients earlier in the disease course and be aware of the extrahepatic manifestations of NAFLD to improve liver disease outcomes. In this review, we focus on the monitoring and management of the extrahepatic manifestations of NAFLD.

참고문헌 (147)

  1. Chalasani N, "The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases", Hepatology, 67, pp.328~357 (2018)
  2. Younossi ZM, "Global epidemiology of nonalcoholic fatty liver disease-metaanalytic assessment of prevalence, incidence, and outcomes", Hepatology, 64, pp.73~84 (2016)
  3. Estes C, "Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease", Hepatology, 67, pp.123~133 (2018)
  4. Eslam M, "MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease", Gastroenterology, 158, pp.1999~2014.e1 (2020)
  5. Younossi ZM, "From NAFLD to MAFLD: implications of a premature change in terminology", Hepatology, 73, pp.1194~1198 (2021)
  6. Byrne CD, "NAFLD: a multisystem disease", J Hepatol, 62(1 Suppl), pp.S47~S64 (2015)
  7. Andrew A. Li, "Extrahepatic Manifestations of Nonalcoholic Fatty Liver Disease", Gut and Liver, 14(2), pp.168~178 (2020), 거트앤리버 소화기연관학회협의회
  8. Adams LA, "Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases", Gut, 66, pp.1138~1153 (2017)
  9. Angulo P, "Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease", Gastroenterology, 149, pp.389~397.e10 (2015)
  10. Ekstedt M, "Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up", Hepatology, 61, pp.1547~1554 (2015)
  11. Kim D, "Trends in mortality from extrahepatic complications in patients with chronic liver disease, from 2007 through 2017", Gastroenterology, 157, pp.1055~1066.e11 (2019)
  12. Targher G, "Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease", N Engl J Med, 363, pp.1341~1350 (2010)
  13. Marchesini G, "Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome", Hepatology, 37, pp.917~923 (2003)
  14. Targher G, "Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis", J Hepatol, 65, pp.589~600 (2016)
  15. Yoshitaka H, "Nonoverweight nonalcoholic fatty liver disease and incident cardiovascular disease: a post hoc analysis of a cohort study", Medicine (Baltimore), 96, pp.e6712~ (2017)
  16. Targher G, "NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications", Gut, 69, pp.1691~1705 (2020)
  17. Kim D, "Nonalcoholic fatty liver disease is associated with coronary artery calcification", Hepatology, 56, pp.605~613 (2012)
  18. Park HE, "Nonalcoholic fatty liver disease is associated with coronary artery calcification development: a longitudinal study", J Clin Endocrinol Metab, 101, pp.3134~3143 (2016)
  19. Wong CR, "The association between nonalcoholic fatty liver disease and cardiovascular disease outcomes", Clin Liver Dis (Hoboken), 12, pp.39~44 (2018)
  20. European Association for the Study of the Liver (EASL), "EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease", J Hepatol, 64, pp.1388~1402 (2016)
  21. Vilar-Gomez E, "Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis", Gastroenterology, 149, pp.367~378.e5 (2015)
  22. Fontana L, "Long-term calorie restriction is highly effective in reducing the risk for atherosclerosis in humans", Proc Natl Acad Sci U S A, 101, pp.6659~6663 (2004)
  23. Dyson JK, "Non-alcoholic fatty liver disease: a practical approach to treatment", Frontline Gastroenterol, 5, pp.277~286 (2014)
  24. Haufe S, "Randomized comparison of reduced fat and reduced carbohydrate hypocaloric diets on intrahepatic fat in overweight and obese human subjects", Hepatology, 53, pp.1504~1514 (2011)
  25. Chitturi S, "The Asia-Pacific working party on non-alcoholic fatty liver disease guidelines 2017-part 2: management and special groups", J Gastroenterol Hepatol, 33, pp.86~98 (2018)
  26. Chen H, "Consumption of sugar-sweetened beverages has a dose-dependent effect on the risk of non-alcoholic fatty liver disease: an updated systematic review and dose-response meta-analysis", Int J Environ Res Public Health, 16, pp.2192~ (2019)
  27. Wijarnpreecha K, "Associations of sugar- and artificially sweetened soda with nonalcoholic fatty liver disease: a systematic review and meta-analysis", QJM, 109, pp.461~466 (2016)
  28. Zelber-Sagi S, "High red and processed meat consumption is associated with nonalcoholic fatty liver disease and insulin resistance", J Hepatol, 68, pp.1239~1246 (2018)
  29. Noureddin M, "Diet associations with nonalcoholic fatty liver disease in an ethnically diverse population: the multiethnic cohort", Hepatology, 71, pp.1940~1952 (2020)
  30. Gepner Y, "The beneficial effects of Mediterranean diet over low-fat diet may be mediated by decreasing hepatic fat content", J Hepatol, 71, pp.379~388 (2019)
  31. Estruch R, "Primary prevention of cardiovascular disease with a mediterranean diet supplemented with extra-virgin olive oil or nuts", N Engl J Med, 378, pp.e34~ (2018)
  32. Asbaghi O, "Effects of the Mediterranean diet on cardiovascular risk factors in non-alcoholic fatty liver disease patients: a systematic review and meta-analysis", Clin Nutr ESPEN, 37, pp.148~156 (2020)
  33. Saab S, "Impact of coffee on liver diseases: a systematic review", Liver Int, 34, pp.495~504 (2014)
  34. Nordestgaard AT, "Coffee intake, cardiovascular disease and all-cause mortality: observational and Mendelian randomization analyses in 95 000-223 000 individuals", Int J Epidemiol, 45, pp.1938~1952 (2016)
  35. Chen YP, "A systematic review and a dose-response meta-analysis of coffee dose and nonalcoholic fatty liver disease", Clin Nutr, 38, pp.2552~2557 (2019)
  36. Brown OI, "Coffee reduces the risk of death after acute myocardial infarction: a meta-analysis", Coron Artery Dis, 27, pp.566~572 (2016)
  37. Kim D, "Inadequate physical activity and sedentary behavior are independent predictors of nonalcoholic fatty liver disease", Hepatology, 72, pp.1556~1568 (2020)
  38. Gerber L, "Nonalcoholic fatty liver disease (NAFLD) is associated with low level of physical activity: a population-based study", Aliment Pharmacol Ther, 36, pp.772~781 (2012)
  39. Shiroma EJ, "Physical activity and cardiovascular health: lessons learned from epidemiological studies across age, gender, and race", ethnicity, 2010, pp.122, 743~752
  40. van der Windt DJ, "The effects of physical exercise on fatty liver disease", Gene Expr, 18, pp.89~101 (2018)
  41. Hallsworth K, "Modified high-intensity interval training reduces liver fat and improves cardiac function in non-alcoholic fatty liver disease: a randomized controlled trial", Clin Sci (Lond), 129, pp.1097~1105 (2015)
  42. Lin JS, "Behavioral counseling to promote a healthy lifestyle in persons with cardiovascular risk factors: a systematic review for the U.S. Preventive Services Task Force", Ann Intern Med, 161, pp.568~578 (2014)
  43. Keating SE, "Exercise and nonalcoholic fatty liver disease: a systematic review and meta-analysis", J Hepatol, 57, pp.157~166 (2012)
  44. Kim D, "Physical activity, measured objectively, is associated with lower mortality in patients with nonalcoholic fatty liver disease", Clin Gastroenterol Hepatol (2020)[DOI]
  45. Thoma C, "Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: a systematic review", J Hepatol, 56, pp.255~266 (2012)
  46. Ismaiel A, "How to reduce cardiovascular risk in nonalcoholic fatty liver disease", Am J Ther (2020)[DOI]
  47. Cholankeril R, "Anti-diabetic medications for the pharmacologic management of NAFLD", Diseases, 6, pp.93~ (2018)
  48. Lexis CP, "The effect of metformin on cardiovascular risk profile in patients without diabetes presenting with acute myocardial infarction: data from the glycometabolic intervention as adjunct to primary coronary intervention in st elevation myocardial infarction (GIPS-III) trial", BMJ Open Diabetes Res Care, 3, pp.e000090~ (2015)
  49. Griffin SJ, "Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes", Diabetologia, 60, pp.1620~1629 (2017)
  50. Musso G, "A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease", Hepatology, 52, pp.79~104 (2010)
  51. Li Y, "Metformin in non-alcoholic fatty liver disease: a systematic review and meta-analysis", Biomed Rep, 1, pp.57~64 (2013)
  52. Aithal GP, "Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis", Gastroenterology, 135, pp.1176~1184 (2008)
  53. Cusi K, "Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial", Ann Intern Med, 165, pp.305~315 (2016)
  54. Sanyal AJ, "Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis", N Engl J Med, 362, pp.1675~1685 (2010)
  55. Liao HW, "Pioglitazone and cardiovascular outcomes in patients with insulin resistance, pre-diabetes and type 2 diabetes: a systematic review and meta-analysis", BMJ Open, 7, pp.e013927~ (2017)
  56. Zhu J, "Association of glucose-lowering medications with cardiovascular outcomes: an umbrella review and evidence map", Lancet Diabetes Endocrinol, 8, pp.192~205 (2020)
  57. Armstrong MJ, "Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program", Aliment Pharmacol Ther, 37, pp.234~242 (2013)
  58. Armstrong MJ, "Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study", Lancet, 387, pp.679~690 (2016)
  59. Petit JM, "Effect of liraglutide therapy on liver fat content in patients with inadequately controlled type 2 diabetes: the lira-NAFLD study", J Clin Endocrinol Metab, 102, pp.407~415 (2017)
  60. Svanström H, "Use of liraglutide and risk of major cardiovascular events:a register-based cohort study in Denmark and Sweden", Lancet Diabetes Endocrinol, 7, pp.106~114 (2019)
  61. Howell R, "Clinical potential of liraglutide in cardiovascular risk reduction in patients with type 2 diabetes:evidence to date", Diabetes Metab Syndr Obes, 12, pp.505~512 (2019)
  62. Raj H, "SGLT-2 inhibitors in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: a systematic review", World J Diabetes, 10, pp.114~132 (2019)
  63. Rabizadeh S, "Cardiovascular and renal benefits of SGLT2 inhibitors: a narrative review", Int J Endocrinol Metab, 17, pp.e84353~ (2019)
  64. Arnott C, "Sodium-glucose cotransporter 2 inhibition for the prevention of cardiovascular events in patients with type 2 diabetes mellitus: a systematic review and meta-analysis", J Am Heart Assoc, 9, pp.e014908~ (2020)
  65. Singh M, "Risks associated with SGLT2 inhibitors: an overview", Curr Drug Saf, 13, pp.84~91 (2018)
  66. Yilmaz Y, "Effects of sitagliptin in diabetic patients with nonalcoholic steatohepatitis", Acta Gastroenterol Belg, 75, pp.240~244 (2012)
  67. Iwasaki T, "Sitagliptin as a novel treatment agent for non-alcoholic fatty liver disease patients with type 2 diabetes mellitus", Hepatogastroenterology, 58, pp.2103~2105 (2011)
  68. Joy TR, "Sitagliptin in patients with nonalcoholic steatohepatitis:a randomized, placebo-controlled trial", World J Gastroenterol, 23, pp.141~150 (2017)
  69. Alam S, "Effect of sitagliptin on hepatic histological activity and fibrosis of nonalcoholic steatohepatitis patients: a 1-year randomized control trial", Hepat Med, 10, pp.23~31 (2018)
  70. Green JB, "Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes", N Engl J Med, 373, pp.232~242 (2015)
  71. Khalse M, "A review on cardiovascular outcome studies of dipeptidyl peptidase-4 inhibitors", Indian J Endocrinol Metab, 22, pp.689~695 (2018)
  72. Kohsaka S, "Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4inhibitors: an analysis from the CVD-REAL 2 multinational cohort study", Lancet Diabetes Endocrinol, 8, pp.606~615 (2020)
  73. Athyros VG, "The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of nonalcoholic fatty liver disease", nonalcoholic steatohepatitis and related cardiovascular risk. An expert panel statement, 2017, pp.71, 17~32
  74. Arnett DK, "2019 ACC", AHA guideline on the primary prevention of cardiovascular disease: executive summary: a report of the American College of Cardiology, J Am Coll Cardiol, pp.2019, 74[DOI]
  75. Hyogo H, "Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia", Metabolism, 57, pp.1711~1718 (2008)
  76. Ekstedt M, "Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study", J Hepatol, 47, pp.135~141 (2007)
  77. Kimura Y, "Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH", J Gastroenterol, 45, pp.750~757 (2010)
  78. Foster T, "Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St Francis Heart Study randomized clinical trial", Am J Gastroenterol, 106, pp.71~77 (2011)
  79. Lewis JH, "Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease:results of a prospective, randomized, double-blind, placebocontrolled, multicenter trial", Hepatology, 46, pp.1453~1463 (2007)
  80. Sigler MA, "An evidence-based review of statin use in patients with nonalcoholic fatty liver disease", Clin Med Insights Gastroenterol, 11 (2018)
  81. Tzefos M, "3-hydroxyl-3-methylglutaryl coenzyme A reductase inhibitor use in chronic liver disease: a therapeutic controversy", J Clin Lipidol, 5, pp.450~459 (2011)
  82. Sanyal AJ, "No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial", Gastroenterology, 147, pp.377~384.e1 (2014)
  83. Argo CK, "Effects of n-3 fish oil on metabolic and histological parameters in NASH: a double-blind, randomized, placebo-controlled trial", J Hepatol, 62, pp.190~197 (2015)
  84. Lan M, "Omega-3 fatty acid supplements for the prevention of cardiovascular disease", Sr Care Pharm, 35, pp.318~323 (2020)
  85. Bowen KJ, "Omega-3 fatty acids and cardiovascular disease: are there benefits?", Curr Treat Options Cardiovasc Med, 18, pp.69~ (2016)
  86. Myung SK, "Efficacy of vitamin and antioxidant supplements in prevention of cardiovascular disease: systematic review and meta-analysis of randomised controlled trials", BMJ, 346, pp.10~ (2013)
  87. Vivekananthan DP, "Use of antioxidant vitamins for the prevention of cardiovascular disease:meta-analysis of randomised trials", Lancet, 361, pp.2017~2023 (2003)
  88. Lindor KD, "Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial", Hepatology, 39, pp.770~778 (2004)
  89. Younossi ZM, "Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial", Lancet, 394, pp.2184~2196 (2019)
  90. Simon TG, "Daily aspirin use associated with reduced risk for fibrosis progression in patients with nonalcoholic fatty liver disease", Clin Gastroenterol Hepatol, 17, pp.2776~2784.e4 (2019)
  91. Jiang ZG, "Aspirin use is associated with lower indices of liver fibrosis among adults in the United States", Aliment Pharmacol Ther, 43, pp.734~743 (2016)
  92. Zhu Q, "Therapeutic effect of renin angiotensin system inhibitors on liver fibrosis", J Renin Angiotensin Aldosterone Syst, 17 (2016)
  93. Lee Y, "Complete resolution of nonalcoholic fatty liver disease after bariatric surgery: a systematic review and meta-analysis", Clin Gastroenterol Hepatol, 17, pp.1040~1060.e11 (2019)
  94. Klebanoff MJ, "Bariatric surgery for nonalcoholic steatohepatitis: a clinical and cost-effectiveness analysis", Hepatology, 65, pp.1156~1164 (2017)
  95. Mathurin P, "Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease", Gastroenterology, 137, pp.532~540 (2009)
  96. Laursen TL, "Bariatric surgery in patients with non-alcoholic fatty liver disease - from pathophysiology to clinical effects", World J Hepatol, 11, pp.138~149 (2019)
  97. Lassailly G, "Bariatric surgery reduces features of nonalcoholic steatohepatitis in morbidly obese patients", Gastroenterology, 149, pp.379~388 (2015)
  98. Moussa O, "Effect of bariatric surgery on long-term cardiovascular outcomes: a nationwide nested cohort study", Eur Heart J, 41, pp.2660~2667 (2020)
  99. Benraouane F, "Reductions in cardiovascular risk after bariatric surgery", Curr Opin Cardiol, 26, pp.555~561 (2011)
  100. VanWagner LB, "Extrahepatic manifestations of nonalcoholic fatty liver disease", Curr Hepatol Rep, 15, pp.75~85 (2016)
  101. Chitturi S, "NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome", Hepatology, 35, pp.373~379 (2002)
  102. Younossi ZM, "The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis", J Hepatol, 71, pp.793~801 (2019)
  103. Mantovani A, "Nonalcoholic fatty liver disease and risk of incident type 2 diabetes: a meta-analysis", Diabetes Care, 41, pp.372~382 (2018)
  104. Armstrong MJ, "Extrahepatic complications of nonalcoholic fatty liver disease", Hepatology, 59, pp.1174~1197 (2014)
  105. Noureddin M, "Screening for nonalcoholic fatty liver disease in persons with type 2 diabetes in the United States is cost-effective: a comprehensive cost-utility analysis", Gastroenterology, 159, pp.1985~1987 (2020)
  106. Targher G, "Risk of chronic kidney disease in patients with non-alcoholic fatty liver disease: is there a link?", J Hepatol, 54, pp.1020~1029 (2011)
  107. Targher G, "Relationship between kidney function and liver histology in subjects with nonalcoholic steatohepatitis", Clin J Am Soc Nephrol, 5, pp.2166~2171 (2010)
  108. Targher G, "Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative", laser-treated retinopathy in type 2 diabetic patients, 2008, pp.51, 444~450
  109. Kaps L, "Non-alcoholic fatty liver disease increases the risk of incident chronic kidney disease", United European Gastroenterol J, 8, pp.942~948 (2020)
  110. Byrne CD, "NAFLD as a driver of chronic kidney disease", J Hepatol, 72, pp.785~801 (2020)
  111. Marcuccilli M, "NAFLD and chronic kidney disease", Int J Mol Sci, 17, pp.562~ (2016)
  112. Jang HR, "Nonalcoholic fatty liver disease accelerates kidney function decline in patients with chronic kidney disease: a cohort study", Sci Rep, 8, pp.4718~ (2018)
  113. Musso G, "Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis", PLoS Med, 11, pp.e1001680~ (2014)
  114. Wijarnpreecha K, "Nonalcoholic fatty liver disease and albuminuria: a systematic review and meta-analysis", Eur J Gastroenterol Hepatol, 30, pp.986~994 (2018)
  115. Paik JM, "Mortality related to nonalcoholic fatty liver disease is increasing in the United States", Hepatol Commun, 3, pp.1459~1471 (2019)
  116. Allen AM, "The risk of incident extrahepatic cancers is higher in non-alcoholic fatty liver disease than obesity - a longitudinal cohort study", J Hepatol, 71, pp.1229~1236 (2019)
  117. Liu SS, "Association between nonalcoholic fatty liver disease and extrahepatic cancers: a systematic review and meta-analysis", Lipids Health Dis, 19, pp.118~ (2020)
  118. Mesarwi OA, "Obstructive sleep apnea, hypoxia, and nonalcoholic fatty liver disease", Am J Respir Crit Care Med, 199, pp.830~841 (2019)
  119. Jin S, "Association between obstructive sleep apnea and non-alcoholic fatty liver disease: a systematic review and meta-analysis", Sleep Breath, 22, pp.841~851 (2018)
  120. Umbro I, "Association between non-alcoholic fatty liver disease and obstructive sleep apnea", World J Gastroenterol, 26, pp.2669~2681 (2020)
  121. Aron-Wisnewsky J, "Chronic intermittent hypoxia is a major trigger for non-alcoholic fatty liver disease in morbid obese", J Hepatol, 56, pp.225~233 (2012)
  122. Mishra P, "Apnoeic-hypopnoeic episodes during obstructive sleep apnoea are associated with histological nonalcoholic steatohepatitis", Liver Int, 28, pp.1080~1086 (2008)
  123. Trzepizur W, "Association between severity of obstructive sleep apnea and blood markers of liver injury", Clin Gastroenterol Hepatol, 14, pp.1657~1661 (2016)
  124. Kim D, "Continuous positive airway pressure therapy on nonalcoholic fatty liver disease in patients with obstructive sleep apnea", J Clin Sleep Med, 14, pp.1315~1322 (2018)
  125. Schwartz AR, "Effect of weight loss on upper airway collapsibility in obstructive sleep apnea", Am Rev Respir Dis, 144(1), pp.494~498 (1991)
  126. Smith PL, "Weight loss in mildly to moderately obese patients with obstructive sleep apnea", Ann Intern Med, 103, pp.850~855 (1985)
  127. Chung GE, "Longitudinal change in thyroid-stimulating hormone and risk of nonalcoholic fatty liver disease", Clin Gastroenterol Hepatol, 19, pp.848~849.e1 (2021)
  128. Kim D, "Low-normal thyroid function is associated with advanced fibrosis among adults in the United States", Clin Gastroenterol Hepatol, 17, pp.2379~2381 (2019)
  129. Chung GE, "Nonalcoholic fatty liver disease across the spectrum of hypothyroidism", J Hepatol, 57, pp.150~156 (2012)
  130. Eshraghian A, "Non-alcoholic fatty liver disease and thyroid dysfunction: a systematic review", World J Gastroenterol, 20, pp.8102~8109 (2014)
  131. He W, "Relationship between hypothyroidism and non-alcoholic fatty liver disease: a systematic review and meta-analysis", Front Endocrinol (Lausanne), 8, pp.335~ (2017)
  132. Kim D, "Subclinical hypothyroidism and low-normal thyroid function are associated with nonalcoholic steatohepatitis and fibrosis", Clin Gastroenterol Hepatol, 16, pp.123~131.e1 (2018)
  133. Kim D, "Low thyroid function in nonalcoholic fatty liver disease is an independent predictor of all-cause and cardiovascular mortality", Am J Gastroenterol, 115, pp.1496~1504 (2020)
  134. triazine-6-carbonitrile (MGL-3196), a highly selective thyroid hormone receptor beta agonist in clinical trials for the treatment of dyslipidemia, "J Med Chem", 2014, 3912~3923
  135. Kowalik MA, "Thyroid hormones, thyromimetics and their metabolites in the treatment of liver disease", Front Endocrinol (Lausanne), 9, pp.382~ (2018)
  136. Harrison SA, "Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebocontrolled, phase 2 trial", Lancet, 394, pp.2012~2024 (2019)
  137. Goodman NF, "American Association of Clinical Endocrinologists, American College of Endocrinology, and Androgen Excess and Pcos Society Disease State clinical review: guide to the best practices in the evaluation and treatment of polycystic ovary syndrome--part 1", Endocr Pract, 21, pp.1291~1300 (2015)
  138. Wu J, "A potential link between polycystic ovary syndrome and non-alcoholic fatty liver disease: an update meta-analysis", Reprod Health, 15, pp.77~ (2018)
  139. Kim JJ, "Polycystic ovary syndrome with hyperandrogenism as a risk factor for nonobese non-alcoholic fatty liver disease", Aliment Pharmacol Ther, 45, pp.1403~1412 (2017)
  140. Sarkar M, "Polycystic ovary syndrome (PCOS) is associated with NASH severity and advanced fibrosis", Liver Int, 40, pp.355~359 (2020)
  141. Paschou SA, "Nonalcoholic fatty liver disease in women with polycystic ovary syndrome", Endocrine, 67, pp.1~8 (2020)
  142. Vassilatou E., "Nonalcoholic fatty liver disease and polycystic ovary syndrome", World J Gastroenterol, 20, pp.8351~8363 (2014)
  143. Miele L, "Prevalence, characteristics and severity of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis", J Hepatol, 51, pp.778~786 (2009)
  144. Gisondi P, "Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis", J Hepatol, 51, pp.758~764 (2009)
  145. Wenk KS, "Psoriasis and non-alcoholic fatty liver disease", J Eur Acad Dermatol Venereol, 25, pp.383~391 (2011)
  146. Phan K, "Relationship between psoriasis and non-alcoholic fatty liver disease - updated systematic review and adjusted meta-analysis", Australas J Dermatol, 60, pp.e352~e355 (2019)
  147. Campanati A, "The effect of etanercept on hepatic fibrosis risk in patients with non-alcoholic fatty liver disease, metabolic syndrome, and psoriasis", J Gastroenterol, 48, pp.839~846 (2013)

관련 논문AI추천

Extrahepatic Manifestations of Nonalcoholic Fatty Liver DiseaseAijaz Ahmed, Andrew A. Li, Donghee Kim거트앤리버 소화기연관학회협의회 · Gut and Liver2020 · 제14권 제2호Nonalcoholic fatty liver disease and non-liver comorbiditiesMindie H. Nguyen, Richie Manikat대한간학회 · Clinical and Molecular Hepatology2023 · 제29권 제2호Causes and risk profiles of mortality among individuals with nonalcoholic fatty liver diseaseAijaz Ahmed, Donghee Kim, Peter Konyn대한간학회 · Clinical and Molecular Hepatology2023 · 제29권 제1호Nonalcoholic Fatty Liver Disease as a Systemic Disease and the Need for Multidisciplinary CareIwaki Michihiro, Kobayashi Takashi, Nakajima Atsushi, Nogami Asako, Saito Satoru, Yoneda Masato거트앤리버 소화기연관학회협의회 · Gut and Liver2023 · 제17권 제6호Risk factors in nonalcoholic fatty liver disease전대원, Eileen L. Yoon, Eunji Ko대한간학회 · Clinical and Molecular Hepatology2023 · 제29권 제1호Global incidence of adverse clinical events in nonalcoholic fatty liver disease: A systematic review and meta-analysisChristopher D. Stave, David M. Le, Fanpu Ji, Hansen Dang, KeeSeok Lee, Michael H. Le, Mindie H. Nguyen, Ramsey Cheung, Takanori Ito, Thomas C. Baez, Vy H. Nguyen, Yee Hui Yeo, Yuankai Wu대한간학회 · Clinical and Molecular Hepatology2024 · 제30권 제2호

이 간행물의 다른 논문 (14건)

Optimizing the management of intermediate-stage hepatocellular carcinoma: Current trends and prospectsHideki Iwamoto, Takuji Torimurapp. 236-245Current and future strategies for the treatment of chronic hepatitis COmar Alshuwaykh, Paul Y. Kwopp. 246-256From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple?Korean NAFLD Study Group, Yuri Cho, Soung Won Jeong, Jin-Woo Lee, Seong Hee Kang, Seung Up Kimpp. 257-269A need for patient-centered care in managing patients with liver cirrhosisYoon Eileen L.pp. 270-272Negligible risk of hepatocellular carcinoma in chronic hepatitis B patients in immune-tolerant phase: Myth or factGrace Lai-Hung Wong, Vincent Wai-Sun Wong, Terry Cheuk-Fung Yippp. 273-277
원문 보기